The Evolution and Ecology of Resistance in Cancer Therapy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Despite continuous deployment of new treatment strategies and agents over many decades, most disseminated cancers remain fatal. Cancer cells, through their access to the vast information of human genome, have a remarkable capacity to deploy adaptive strategies for even the most effective treatments. We note there are two critical steps in the clinical manifestation of treatment resistance. The first, which is widely investigated, requires deployment of a mechanism of resistance that usually involves increased expression of molecular machinery necessary to eliminate the cytotoxic effect of treatment. However, the emergence of a resistant phenotype is not in itself clinically significant. That is, resistant cells affect patient outcomes only when they form a sufficiently large population to allow tumor progression and treatment failure. Importantly, proliferation of the resistant phenotype is by no means certain and, in fact, depends on complex Darwinian dynamics governed by the costs and benefits of the resistance mechanisms in the context of the local environment and competing populations. Attempts to target molecular machinery of resistance have had little clinical success largely because of the diversity within the human genome-therapeutic interruption of one mechanism simply results in its replacement by an alternative. We explore an alternative strategy for overcoming treatment resistance that seeks to understand and exploit the critical evolutionary dynamics that govern proliferation of the resistant phenotypes. In general, this approach has shown that, although emergence of resistance mechanisms in cancer cells to every current therapy is inevitable, proliferation of the resistant phenotypes is not and can be delayed and even prevented with sufficient understanding of the underlying ecoevolutionary dynamics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Self-citationTetraploidy, aneuploidy and cancer
Ganem, N. J., Storchova, Z., & Pellman, D. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.02.011 · Cited by 668
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Quantitative Imaging in Cancer Evolution and Ecology
Gatenby, R. A., Grove, O., & Gillies, R. J. (2013) · Radiology · doi:10.1148/radiol.13122697 · Cited by 515
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
The peppered moth and industrial melanism: evolution of a natural selection case study
Cook, L. M., & Saccheri, I. J. (2013) · Heredity · doi:10.1038/hdy.2012.92 · Cited by 228
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197
Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.484801 · Cited by 126
Cited by
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Cancer as a disease of old age: changing mutational and microenvironmental landscapes
Laconi, E., Marongiu, F., & DeGregori, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0721-1 · Cited by 348
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227
Self-citationFrom reinforcement learning to agency: Frameworks for understanding basal cognition
Seifert, G., Sealander, A., Marzen, S., & Levin, M. (2024) · BioSystems · doi:10.1016/j.biosystems.2023.105107 · Cited by 16
Metadata
- Authors
- Gatenby, R., & Brown, J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-07-14
- Volume
- 8
- Issue
- 3
- Pages
- a033415
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2735758359
- Cited by
- 130
- References
- 11
- Type
- posted content
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.